Peginterferon lambda-1a (ZymoGenetics)

N/A

Report date: 2026/05/06 20:02:28

Base Information

Drug NamePeginterferon lambda-1a (ZymoGenetics)
Drug Alias NamePEG-interleukin-29 - ZymoGeneticsPEG-rIL-29 - ZymoGeneticsPEG-IL-29 - ZymoGeneticsLambda - Eiger BioPharmaceuticalsPEG-interferon lambda +[6] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterferon lambda receptor stimulants
TargetsInterferon lambda receptor
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Hepatitis D, ChronicHepatitis D +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[40] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Health Network (Uhn)Zymogenetics Inc
China Registration ClassN/A

Develop Information

Active CompaniesEiger Biopharmaceuticals IncUniversity Health Network (Uhn)
Inactive CompaniesBristol Myers Squibb SrlcompanyZymogenetics IncStanford University +[5] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)Hepatitis D
Inactive IndicationsHepatitis D, ChronicHepatitis C, ChronicHepatitis C +[5] 

Other Information

ATC CodeN/A
Related LinksN/A